| 张慧勤,胡晨曦,惠开元,等.非小细胞肺癌外周血 T细胞表面程序性细胞死亡因子 1的表达与免疫治疗疗效的相关性研究[J].安徽医药,2023,27(4):706-711. |
| 非小细胞肺癌外周血 T细胞表面程序性细胞死亡因子 1的表达与免疫治疗疗效的相关性研究 |
| Correlation of PD-1 expression on peripheral blood T cells in non-small cell lung cancer and the efficacy of immunotherapy |
| |
| DOI：10.3969/j.issn.1009-6469.2023.04.016 |
| 中文关键词: 癌，非小细胞肺 程序性细胞死亡因子 1 抗体，单克隆 T细胞 免疫治疗 疗效评估 |
| 英文关键词: Carcinoma, non-small-cell lung Programmed cell death protein 1 (PD-1) Antibodies, monoclonal T cells Immunotherapy Efficacy evaluation |
| 基金项目:江苏省研究生科研与实践创新计划( SJCX21_1152) |
|
| 摘要点击次数: 664 |
| 全文下载次数: 216 |
| 中文摘要: |
| 目的探讨非小细胞肺癌( NSCLC)病人外周血 CD3+T细胞、 CD4+T细胞、 CD8+T细胞表面的免疫检查点程序性细胞死亡因子 1(PD-1)的表达情况及其与 PD-1单抗治疗疗效的相关性分析。方法选取 2020年 9月至 2021年 12月在连云港市第一人民医院初步诊断为非小细胞肺癌的病人 50例，另外选取该院体检中心的健康体检者 40例为本研究的健康对照组。采用流式细胞术( FCM)检测 50例 NSCLC病人和 40例健康对照者的外周血 CD3+、CD4+、CD8+T淋巴细胞表面 PD-1的表达水平，分析其与临床特征的关系；所有 NSCLC病人均接受 PD-1单抗治疗，每周期用药前检测 PD-1的表达水平，后通过实体瘤免疫疗效评价标准( iRECIST)疗效评价，将病人分为治疗缓解组和治疗耐药组，观察免疫治疗疗效与 PD-1的水平变化之间的相关性。结果 |
| 英文摘要: |
| Objective To investigate the expression of the immunocheckpoint blockades programmed cell death protein 1 (PD-1) on the surface of CD3+ T cells, CD4+ T cells and CD8+ T cells in peripheral blood of patients with non-small cell lung cancer (NSCLC) and its correlation with the therapeutic efficacy of PD-1 monoclonal antibody.Methods Fifty patients who were initially diagnosed withNSCLC from September 2020 to December 2021 at the Lianyungang First People′s Hospital were selected, and 40 healthy physical examination participants from the hospital′s physical examination center were selected as the healthy control group for this study. Flow cytometry (FCM) was used to detect the expression levels of PD-1 on the surface of CD3+, CD4+, CD8+ T lymphocytes in peripheral bloodof 50 NSCLC patients and 40 healthy controls, and the relationship between them and clinical characteristics was analyzed; NSCLC patients were treated with PD-1 monoclonal antibody, and the expression level of PD-1 was detected before each cycle of treatment. Afterevaluation of the efficacy of immune Response Evaluation Criteria in Solid Tumors (iRECIST), the patients were divided into treatmentremission group and treatment resistant group, and the correlation between the efficacy of immunotherapy and the level of PD-1 was observed.Results The expression ratio of PD-1 on the surface of CD3+, CD4+, CD8+ T lymphocytes in peripheral blood of patients with NSCLC was higher than that in healthy controls: (15.57±8.35) vs. (6.01±2.22), (16.02±8.66) vs. (5.70±2.32), (17.23±9.07) vs. (6.29± 2.65), and the expression of PD-1 on the surface of CD3+, CD4+, CD8+ T lymphocytes was associated with clinical stage, lymph node metastasis , distant metastasis and overall survival (P<0.05). The expression ratio of PD-1 on the peripheral blood T lymphocytes of the patients in the immunotherapy remission group was significantly lower than that of the patients before treatment (P<0.05); the expression ratio of PD-1 in the immunotherapy resistant group was significantly higher than that in the immunotherapy remission group (P<0.05). Conclusion The expression of PD-1 on the surface of CD3+, CD4+, CD8+ T lymphocytes in peripheral blood of patients with NSCLC is significantly correlated with clinical stage, distant metastasis and overall survival, which provides help for the early diagnosis and auxiliary staging of NSCLC patients and becomes a PD-1 monolayer antibiotic evaluation index to guide medication. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
